Scynexis Presents Interim Ibrexafungerp Data In Hospital-Based Fungal Infections

  • Scynexis Inc SCYX announced an oral presentation of interim data analyses from its ongoing Phase 3 FURI study of oral ibrexafungerp in severe hospital-based fungal infections.
  • Related Link: Scynexis' Brexafemme For Vaginal Yeast Infections Secures 10 Years Regulatory Exclusivity.
  • Of the 74 patients treated with oral ibrexafungerp 62.1% showed complete or partial response, 24.3% achieved stable disease, 6.8% showed progressive disease, and 5.4% were indeterminate. 
  • One patient died due to an unrelated cause.
  • In addition, Scynexis is presenting two posters that discuss sub-populations from the FURI study with difficult-to-treat infections.
  • The presentation highlights a sub-analysis of 24 patients (83.3% were refractory) from the Phase 3 FURI study with esophageal candidiasis (EC) or oropharyngeal candidiasis (OPC) treated with oral ibrexafungerp. 
  • Of these patients, 62.5% showed complete or partial response, 29.2% achieved stable disease, and 16.7% showed progressive disease.
  • Sub-analysis of eight patients with Candida bone and joint infections from the Phase 3 FURI study showed 62.5% showed complete or partial response, 12.5% achieved stable disease, and 12.5% showed progressive disease. 
  • One patient was considered indeterminate.
  • Price Action: SCYX is down 1.24% at $5.41 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!